Form 4 for BRTX BioRestorative Therapies, Inc.
Accepted 2023-04-04 00:00:00 ET · period of report 2023-03-31 · accession 0001021771-23-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-04 | 2023-03-31 | BRTX | Silva Francisco | VP of Research, Development, Dir, 10% | P - Purchase | $3.56 | +747 | 159.7K | +0.5% | +$2,659 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-31 | P | A | 747 | $3.56 | 159,690 | D | — | — | (F1) Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. |